Phase III randomized placebo-controlled study in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of complete disease remission on …
Akari Therapeutics Announces Appointment of Chief Financial Officer
NEW YORK and LONDON, July 1, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a …
[Read more...] about Akari Therapeutics Announces Appointment of Chief Financial Officer
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC
NEW YORK and LONDON, July 1, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a …
Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients
Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid …
Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date Interim Phase II bullous pemphigoid (BP) data demonstrated a rapid …
